Empagliflozin, a selective sodium-glucose cotransporter-2 (SGLT2) inhibitor, has emerged as a particularly promising therapeutic option for patients who have both NAFLD and type 2 diabetes. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.